M Kaiserova1, Z Grambalova1, P Otruba1, D Stejskal2,3,4, H Prikrylova Vranova1, J Mares1, K Mensikova1, P Kanovsky1. 1. Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic. 2. AGEL Research and Training Institute, Prostejov, Czech Republic. 3. Institute of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic. 4. Department of Biochemical Sciences, Faculty of Medicine, Ostrava University, Ostrava, Czech Republic.
Abstract
BACKGROUND: Various cerebrospinal fluid (CSF) biomarkers are being studied to improve the sensitivity and specificity of the diagnostic methods for amyotrophic lateral sclerosis (ALS). AIMS OF THE STUDY: The aim of our study was to establish the CSF levels of chromogranin A (CgA) and phosphorylated neurofilament heavy chain (pNF-H) in patients with ALS in order to assess these proteins as possible biomarkers of ALS. METHODS: Cerebrospinal fluid levels of CgA and pNF-H were examined and mutually compared in 15 patients with sporadic ALS and 16 gender- and age-matched controls. RESULTS: Lumbar CSF CgA levels were increased in the patients with ALS compared to the controls (median 235 vs 138, P=.031). Lumbar CSF pNF-H levels were significantly increased in the patients with ALS compared to the control group (median 3091 vs 213, P<.0001). CONCLUSIONS: Identifying CSF biomarkers in ALS is important in order to establish the diagnosis in the early stages of the disease. pNF-H seems to be a good biomarker for the diagnosis of ALS. If confirmed on a larger group of patients, CgA may also become useful in the diagnosis of sporadic ALS.
BACKGROUND: Various cerebrospinal fluid (CSF) biomarkers are being studied to improve the sensitivity and specificity of the diagnostic methods for amyotrophic lateral sclerosis (ALS). AIMS OF THE STUDY: The aim of our study was to establish the CSF levels of chromogranin A (CgA) and phosphorylated neurofilament heavy chain (pNF-H) in patients with ALS in order to assess these proteins as possible biomarkers of ALS. METHODS: Cerebrospinal fluid levels of CgA and pNF-H were examined and mutually compared in 15 patients with sporadic ALS and 16 gender- and age-matched controls. RESULTS: Lumbar CSF CgA levels were increased in the patients with ALS compared to the controls (median 235 vs 138, P=.031). Lumbar CSF pNF-H levels were significantly increased in the patients with ALS compared to the control group (median 3091 vs 213, P<.0001). CONCLUSIONS: Identifying CSF biomarkers in ALS is important in order to establish the diagnosis in the early stages of the disease. pNF-H seems to be a good biomarker for the diagnosis of ALS. If confirmed on a larger group of patients, CgA may also become useful in the diagnosis of sporadic ALS.
Authors: Dorota Koníčková; Kateřina Menšíková; Lucie Tučková; Eva Hényková; Miroslav Strnad; David Friedecký; David Stejskal; Radoslav Matěj; Petr Kaňovský Journal: Biomedicines Date: 2022-07-21
Authors: Raymond Farah; Hayat Haraty; Ziad Salame; Youssef Fares; David M Ojcius; Najwane Said Sadier Journal: Biomed J Date: 2018-05-10 Impact factor: 4.910
Authors: Óscar López-Pérez; Marcos Bernal-Martín; Adelaida Hernaiz; Franc Llorens; Marina Betancor; Alicia Otero; Janne Markus Toivonen; Pilar Zaragoza; Inga Zerr; Juan José Badiola; Rosa Bolea; Inmaculada Martín-Burriel Journal: Biomolecules Date: 2020-05-02